Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 8 February 2024 AM
CSL's 'next-next-gen' Covid vaccine has been shown to last longer than Pfizer's competing mRNA vaccine, mega-blockbuster Comirnaty, in a Phase 3 trial.
The vaccine, produced with partner Arcturus Therapeutics, is ARCT-154, and it's the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine. The approval came last November, from Japan.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.